Celesio Takes Over Laboratoria Flandria
To offer new services through the co-operation between the Celesio subsidiaries
Celesio has acquired Laboratoria Flandria. The acquisition is an addition to the existing network of Celesio’s Belgian subsidiaries.
The company expects to utilise further synergies and to offer new services through the co-operation between the Celesio subsidiaries - Pharma Belgium, Celesio’s pharmacy chain Lloydspharma, Dirk Raes, a provider of cold chain logistics for pharmaceutical manufacturers, and pharmexx Belgium.
The acquisition of Laboratoria Flandria is subject to approval by the Belgian competition authority.
Fritz Oesterle, Chief Executive Officer of Celesio, said: “Together with our wholesaler Pharma Belgium we will achieve significant synergies which will further strengthen Celesio’s position in the Belgian pharmaceutical wholesale market”.
Related Insight
Suppliers Directory
Watson-Marlow Pumps Group - Peristaltic Pumps
Watson-Marlow is the world leader in solving fluid handling problems with peristaltic tubes and hose pumps.
Suppliers
Infotehna Group - Pharmaceutical Software Solutions
Infotehna Group has been in the forefront of global providers of software solutions for the pharmaceutical industry for more than 20 years.
Suppliers
Zenatek - Tracking, Monitoring and Reporting Systems for Goods in Transit
Zenatek is a Company with extensive management experience both in the civil and military logistical fields and in the development of software programming, in particular custom and commercial software. Zenatek was founded to supply services in ICT. It plans, realises and runs systems for dealing with and transmitting data and information on “computer” technology.
Suppliers
CellGenix - High-Quality GMP Reagents for Clinical Ex Vivo Cell Culture
CellGenix is an internationally leading manufacturer and supplier of high quality products in the expanding markets of cell therapy and regenerative medicine.
Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Intelligence
Cloud Computing—Driving Security, Performance and Quality
Published by Medidata Solutions
White Papers
First Application of Haselmeier's Axis-D Injection Pen in Launched
Published by Haselmeier
White Papers
CoreLab Partners Brochure
Published by CoreLab Partners
White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.